Cambria Cannabis ETF

TOKE

Börsenwert 13,5 Mio. $

MANHATTAN BEACH, Calif.--(BUSINESS WIRE)--Cambria Investment Management announced the scheduled liquidation of the Cambria Cannabis ETF (TOKE).

Cannabis ETF spent the first half of the year in the performance doldrums. But they have rallied of late on news that the Trump administration is open to reclassifying marijuana as a less dangerous drug.

One of the hottest topics of the year has been cannabis stocks to buy, especially with elections nearing. We can see that with more than 88% of Americans wanting to see legalization.

On this week's episode of ETF Prime, host Nate Geraci is joined by VettaFi Head of Research Todd Rosenbluth to discuss hedge funds embracing ETFs, spot ether ETFs, and a potential shortage of ETF tickers, among other topics. Afterward, Bancreek CEO and CIO Andrew Skatoff spoke with Geraci about his investment philosophy.

The Canadian cannabis industry is in a shakeout phase, with poorly run businesses struggling and the industry maturing.

Philip Morris beat expectations for both revenues and earnings, driven by robust pricing and increased product volumes.

Morgan Paxhia discusses the latest trends in the cannabis space. He talks about the road to full cannabis legalization in the U.S. He then goes over the best positioned cannabis stocks.

As the first quarter comes to a close, clearly, there have been some thematic winners in terms of flows and investment performance. Artificial Intelligence AI-themed ETFs remain among the top recipients of investor flows this year.

One of the top-performing thematic segments this year is cannabis. A major catalyst has been the proposed descheduling of it from a Schedule I to a Schedule III drug under the Controlled Substances Act (CSA).

Cannabis investors are tired of waiting and losing money, but there are still reasons to be optimistic in the long term.